Harnessing antibody Fc effector functions as therapeutic target

About this project

Monoclonal antibodies have emerged as extremely potent therapeutic molecules that have revolutionized the treatment of cancer and inflammatory diseases. With significant advancements in the field of infectious diseases, there has been an increasing push towards the development and approval of therapeutic anti-viral antibodies. Most if not all of these monoclonal antibodies have been screened and selected for their ability to neutralize and block cellular infection.

In our current research project, we aim to take this one step further and improve upon existing monoclonal antibody therapies by optimizing their Fc effector functions. By leveraging the importance of Fc effector functions, we hope to develop novel investigational monoclonal antibody therapies that are even more effective in treating infectious diseases.